Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Optimizing clozapine treatment.

D Naber1

  • 1Psychiatrische und Nervenklinik, Universität Hamburg, Germany.

The Journal of Clinical Psychiatry
|June 18, 1999
PubMed
Summary
This summary is machine-generated.

Clozapine improves medication compliance in schizophrenia patients, unlike conventional antipsychotics. Careful monitoring minimizes risks, suggesting broader use beyond treatment-resistant cases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of the 'Jumping to conclusions' bias in different subgroups of the at-risk mental state: from cognitive basic symptoms to UHR criteria.

Psychological medicine·2016
Same author

[Comparison of Two Symptom-Triggered Treatments for Alcohol Withdrawal: HAES vs. SAB-P].

Fortschritte der Neurologie-Psychiatrie·2016
Same author

Identification of increased genetic risk scores for schizophrenia in treatment-resistant patients.

Molecular psychiatry·2015
Same author

What are depressive symptoms in acutely ill patients with schizophrenia spectrum disorder?

European psychiatry : the journal of the Association of European Psychiatrists·2014
Same author

Treatment of schizophrenic disorders: Algorithms for acute pharmacotherapy.

International journal of psychiatry in clinical practice·2014
Same author

Correlates of subjective well-being in schizophrenic patients treated with atypical antipsychotics.

International journal of psychiatry in clinical practice·2014
Same journal

Major Depressive Disorder and PTSD Treatment Outcome in Interpersonal Psychotherapy and Prolonged Exposure.

The Journal of clinical psychiatry·2026
Same journal

Psychiatrists and Medical Aid in Dying: Entering Uncharted Waters.

The Journal of clinical psychiatry·2026
Same journal

Mind and Metabolism in Crisis: US Mortality Involving Obesity and Psychiatric Disorders-Trends, Disparities, and ARIMA Projections.

The Journal of clinical psychiatry·2026
Same journal

Generative AI for the Clinical Psychopharmacologist: Is It Ready for Prime Time?

The Journal of clinical psychiatry·2026
Same journal

Posttrauma Benzodiazepine Use and Subsequent PTSD: A Population-Wide Analysis Following Extreme Traumatic Exposure.

The Journal of clinical psychiatry·2026
Same journal

The Challenges of PTSD Prevention: Placing Benzodiazepine Use in Context.

The Journal of clinical psychiatry·2026
See all related articles

Area of Science:

  • Psychiatry
  • Pharmacology

Background:

  • Poor compliance with conventional antipsychotics is a significant challenge in schizophrenia treatment.
  • Treatment side effects, including motor symptoms, often lead to patient noncompliance.

Purpose of the Study:

  • To evaluate clozapine's efficacy and safety profile compared to conventional antipsychotics.
  • To assess clozapine's impact on patient compliance and overall well-being in schizophrenia.

Main Methods:

  • Comparative analysis of patient compliance rates between clozapine and conventional antipsychotics.
  • Review of adverse effect profiles and management strategies for clozapine therapy.
  • Assessment of risk/benefit ratio in treatment-resistant schizophrenic patients.

Main Results:

Related Experiment Videos

  • Clozapine demonstrates minimal extrapyramidal symptoms, significantly improving compliance.
  • Most clozapine-induced adverse effects are manageable with clinical procedures.
  • Hematologic control effectively minimizes the risk of agranulocytosis.

Conclusions:

  • Clozapine offers a favorable risk/benefit ratio for most treatment-resistant schizophrenic patients.
  • Improved patient well-being and compliance warrant broader consideration of clozapine use.
  • Psychiatrists should consider expanding clozapine's application beyond severely resistant cases.